Moreira JN - Search Results

1

Nucleolin Overexpression Predicts Patient Prognosis While Providing a Framework for Targeted Therapeutic Intervention in Lung Cancer.

Valério-Fernandes Â, Fonseca NA, Gonçalves N, Cruz AF, Pereira MI, Gregório AC, Moura V, Ladeirinha AF, Alarcão A, Gonçalves J, Abrunhosa A, Melo JB, Carvalho L, Simões S, Moreira JN. Valério-Fernandes Â, et al. Among authors: moreira jn. Cancers (Basel). 2022 Apr 29;14(9):2217. doi: 10.3390/cancers14092217. Cancers (Basel). 2022. PMID: 35565346 Free PMC article.

2

Technology evaluation: LErafAON, NeoPharm.

Moreira JN, Simões S. Moreira JN, et al. Curr Opin Mol Ther. 2003 Oct;5(5):547-52. Curr Opin Mol Ther. 2003. PMID: 14601525

3

On the formulation of pH-sensitive liposomes with long circulation times.

Simões S, Moreira JN, Fonseca C, Düzgüneş N, de Lima MC. Simões S, et al. Among authors: moreira jn. Adv Drug Deliv Rev. 2004 Apr 23;56(7):947-65. doi: 10.1016/j.addr.2003.10.038. Adv Drug Deliv Rev. 2004. PMID: 15066754 Review.

4

Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells.

Fonseca C, Moreira JN, Ciudad CJ, Pedroso de Lima MC, Simões S. Fonseca C, et al. Among authors: moreira jn. Eur J Pharm Biopharm. 2005 Feb;59(2):359-66. doi: 10.1016/j.ejpb.2004.08.012. Eur J Pharm Biopharm. 2005. PMID: 15661509 Free article.

5

Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.

Moreira JN, Santos A, Simões S. Moreira JN, et al. Rev Recent Clin Trials. 2006 Sep;1(3):217-35. doi: 10.2174/157488706778250050. Rev Recent Clin Trials. 2006. PMID: 18473975 Review.

6

Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing.

Moreira JN, Santos A, Moura V, Pedroso de Lima MC, Simões S. Moreira JN, et al. J Nanosci Nanotechnol. 2008 May;8(5):2187-204. doi: 10.1166/jnn.2008.319. J Nanosci Nanotechnol. 2008. PMID: 18572631 Review.

7

Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer.

Santos A, Sarmento-Ribeiro AB, de Lima MC, Simões S, Moreira JN. Santos A, et al. Among authors: moreira jn. Cytometry A. 2008 Dec;73A(12):1165-72. doi: 10.1002/cyto.a.20634. Cytometry A. 2008. PMID: 18785266 Free article.

8

Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.

Pinto AC, Moreira JN, Simões S. Pinto AC, et al. Among authors: moreira jn. Cancer Chemother Pharmacol. 2009 Aug;64(3):445-54. doi: 10.1007/s00280-008-0892-6. Epub 2008 Dec 23. Cancer Chemother Pharmacol. 2009. PMID: 19104815

9

Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment.

Mendonça LS, Firmino F, Moreira JN, Pedroso de Lima MC, Simões S. Mendonça LS, et al. Among authors: moreira jn. Bioconjug Chem. 2010 Jan;21(1):157-68. doi: 10.1021/bc9004365. Bioconjug Chem. 2010. PMID: 20000596

10

Design of peptide-targeted liposomes containing nucleic acids.

Santos AO, da Silva LC, Bimbo LM, de Lima MC, Simões S, Moreira JN. Santos AO, et al. Among authors: moreira jn. Biochim Biophys Acta. 2010 Mar;1798(3):433-41. doi: 10.1016/j.bbamem.2009.12.001. Epub 2009 Dec 11. Biochim Biophys Acta. 2010. PMID: 20004174 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

83 results

Search Page